Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients

Camillo Porta, Matteo Zimatore, Lucia Bonomi, Ilaria Imarisio, Chiara Paglino, Andrea Sartore-Bianchi, Luciano Mutti

Research output: Contribution to journalArticlepeer-review

Abstract

Within a single-institution phase II trial, we investigated the antitumor activity of the Raltitrexed-Oxaliplatin combination as second-line therapy for malignant pleural mesothelioma (MPM). Fourteen patients were enrolled and all were assessable for response. The trial was then closed because chemotherapy, though well tolerated, yielded no objective responses. The best response observed was disease stabilization in 4 patients only (28.57%), while the other 10 patients (71.42%) progressed despite treatment. Median time to progression (TTP) was 8 weeks (average: 9.85, range: 7-20), while median overall survival was just 14 weeks (average: 21.69, range: 9-66+).

Original languageEnglish
Pages (from-to)429-434
Number of pages6
JournalLung Cancer
Volume48
Issue number3
DOIs
Publication statusPublished - Jun 2005

Keywords

  • Malignant mesothelioma
  • Oxaliplatin
  • Raltitrexed
  • Second-line chemotherapy

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients'. Together they form a unique fingerprint.

Cite this